



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

impacted by the pandemic.<sup>6</sup> Additionally, there are also concerns that the pandemic might have a disproportionate negative effect on other aspects of metabolic health, including provision of metabolic surgery. Despite evidence that metabolic surgery can reduce diabetes-related morbidity and mortality, access to metabolic surgery has historically been undermined compared with other elective surgery due to barriers, including weight stigma.<sup>7</sup>

There is therefore an urgent need to restore both routine and specialist diabetes care as quickly as possible as part of the recovery from the pandemic to prevent further ongoing harm.

DH has received consultancy and speaker fees from Fractyl Health and Sanofi; FR has received consultancy and speaker fees from Medtronic, Ethicon, Novo Nordis, and GI Dynamics. The authors have not received any funding directly related to the subject or content of this work.

\*David Hopkins, Francesco Rubino  
dhopkins3@nhs.net

Department of Diabetes, School of Cardiovascular and Metabolic Medicine and Sciences, King's College London, London, SE5 9RS, UK (DH, FR)

- 1 Steenblock C, Schwarz PEH, Ludwig B, et al. COVID-19 and metabolic disease: mechanisms and clinical management. *Lancet Diabetes Endocrinol* 2021; **9**: 786–98.
- 2 Rawshani A, Kjölhede EA, Rawshani A, et al. Severe COVID-19 in people with type 1 and type 2 diabetes in Sweden: a nationwide retrospective cohort study. *Lancet Reg Health Eur* 2021; **4**: 100105.
- 3 Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. *Lancet Diabetes Endocrinol* 2020; **8**: 813–22.
- 4 Mahamat-Saleh Y, Fiolet T, Rebeaud ME, et al. Diabetes, hypertension, body mass index, smoking and COVID-19-related mortality: a systematic review and meta-analysis of observational studies. *BMJ Open* 2021; **11**: e052777.
- 5 Valbhji J, Barron E, Gorton T, et al. Associations between reductions in routine care delivery and non-COVID-19-related mortality in people with diabetes in England during the COVID-19 pandemic: a population-based parallel cohort study. *Lancet Diabetes Endocrinol* 2022; published online May 27. [https://doi.org/10.1016/S2213-8587\(22\)00131-0](https://doi.org/10.1016/S2213-8587(22)00131-0).
- 6 Seidu S, Hambling C, Holmes P, et al. The impact of the COVID pandemic on primary care diabetes services in the UK: a cross-sectional national survey of views of health professionals delivering diabetes care. *Prim Care Diabetes* 2022; **16**: 257–63.
- 7 Rubino F, Cohen RV, Mingrone G, et al. Bariatric and metabolic surgery during and after the COVID-19 pandemic: DSS recommendations for management of surgical candidates and postoperative patients and prioritisation of access to surgery. *Lancet Diabetes Endocrinol* 2020; **8**: 640–48.

## Impact of BMI on COVID-19 vaccine effectiveness

COVID-19 and obesity are two overlapping pandemics.<sup>1</sup> Individuals with obesity are at risk of developing more severe clinical outcomes as a result of SARS-CoV-2 infection than those without obesity.<sup>2,3</sup> Obesity is also associated with known risk factors for severe COVID-19, such as diabetes and hypertension. Irrespective of comorbidities, excessive weight results in biomechanical and systemic factors that increase the risk of adverse outcomes. Increased abdominal pressure and upward displacement of the diaphragm result in decreased expiratory reserve volume, functional capacity, and respiratory system compliance. Furthermore, obesity-associated alterations in systemic metabolism include insulin resistance, altered adipokines (eg, increased leptin and decreased adiponectin), and chronic low-grade inflammation.<sup>3</sup> Increased inflammatory chemokines might lead to endothelial dysfunction and exacerbate a prothrombotic state. Preliminary research has shown that mice with obesity have an increased duration of viral shedding due to delayed viral clearance, increased number of secondary bacterial infections, and heightened damage to the respiratory epithelium.<sup>4</sup> In addition, COVID-19 vaccine effectiveness might be lower in people with obesity as baseline alterations in systemic cytokine production

might lead to blunted and delayed innate and adaptive immune responses to vaccination.<sup>1</sup> Reduced vaccine effectiveness in people with obesity has been observed for influenza vaccination<sup>5</sup> and preliminary results were suggestive of lower anti-SARS-CoV-2 spike IgG antibody concentrations after two doses of the BNT162b2 mRNA vaccine.<sup>6</sup>

To address the effect of bodyweight on vaccine effectiveness, Carmen Piernas and colleagues<sup>7</sup> in *The Lancet Diabetes & Endocrinology* used a large representative population-based cohort from England of 9 171 524 individuals to investigate severe COVID-19 outcomes after COVID-19 vaccination and associations with BMI. The authors applied multivariable Cox proportional hazard models to estimate the risk of COVID-19 outcomes associated with BMI. Vaccine protection was assessed through a nested matched case-control design to estimate odds ratios in vaccinated versus non-vaccinated people.

Consistent with the findings from phase 3 company-led efficacy trials,<sup>8</sup> the protection of COVID-19 vaccines against severe disease outcomes was high across all BMI categories when comparing people who were vaccinated against those who were unvaccinated. There was a 40–74% lower odds of hospital admission or death after



Published Online  
June 30, 2022  
[https://doi.org/10.1016/S2213-8587\(22\)00170-X](https://doi.org/10.1016/S2213-8587(22)00170-X)  
See [Articles](#) page 571

the second dose in all BMI categories, and 90% lower odds after the third dose.

In the vaccinated cohort, people at the two extremes of BMI distribution (very low and very high BMI) were at greater risk of hospitalisation or death from COVID-19 than people of healthy weight. Despite the large sample size, the study was not powered to address variations in vaccine effectiveness across different vaccine brands and across circulating virus variants. The limitation of their study design was the need to use a matched case-control design, rather than the WHO recommended test-negative design,<sup>9</sup> as the cohort did not include test-negative individuals. Another considerable limitation in interpreting the results for the people who had underweight include potential confounding factors such as frailty, cachexia due to cancer, or other conditions associated with lower BMI, which this study did not capture. Such underlying factors for low weight would inherently have a higher risk of severe COVID-19 outcomes than low weight itself.

There was a high vaccine uptake by people with obesity. Conversely, people who had underweight were less likely to be vaccinated, which might have been an unintended result of public messaging that people with overweight have a higher risk of severe COVID-19, which was corroborated by the UK risk-based strategy of vaccine rollout. These findings should prompt a shift towards more targeted and differentiated public health messaging to enhance vaccine uptake in people who are underweight and who might perceive themselves at lower risk of severe COVID-19.

The finding that vaccine effectiveness is lower in people with higher BMI appears to be robust. Reasons are manifold and might include poorer innate and adaptive immune response.<sup>4</sup> The authors postulate that even with a good serological response there might be an impaired T-cell response that could explain the persistent higher risks of severe COVID-19 outcomes

associated with obesity despite vaccination. Vaccine effectiveness increased with a third dose, which underpins the need for a booster to enhance protection.

This large cohort study emphasises the crucial role of obesity in the COVID-19 pandemic. Obesity and COVID-19 appear to be a detrimental intersection, one that has also been observed for influenza and other infectious diseases.<sup>4</sup> Furthermore, people with obesity in the UK have also been affected by the pandemic lockdown measures with increased overeating, reduced physical activity behaviour, and increased barriers to weight management.<sup>10</sup> Tackling obesity as a societal problem now will help mitigate the disastrous consequences of the current COVID-19 pandemic and those of future pandemics.

AWS serves as consultant to WHO; the opinions expressed here are those of the author and not necessarily those of WHO. AF declares no competing interests.

\*Annelies Wilder-Smith, Annika Frahsa  
anneliesws@gmail.com

Institute of Social and Preventive Medicine, University of Berne, Berne, 3012, Switzerland

- 1 Honce R, Schultz-Cherry S. A tale of two pandemics: obesity and COVID-19. *J Travel Med* 2020; **27**: taaa097.
- 2 Hamer M, Gale CR, Kivimaki M, Batty GD. Overweight, obesity, and risk of hospitalization for COVID-19: a community-based cohort study of adults in the United Kingdom. *Proc Natl Acad Sci USA* 2020; **117**: 21011-13.
- 3 Popkin BM, Du S, Green WD, et al. Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships. *Obes Rev* 2020; **21**: e13128.
- 4 Honce R, Schultz-Cherry S. Influenza in obese travellers: increased risk and complications, decreased vaccine effectiveness. *J Travel Med* 2019; **26**: taz020.
- 5 Neidich SD, Green WD, Rebeles J, et al. Increased risk of influenza among vaccinated adults who are obese. *Int J Obes (Lond)* 2017; **41**: 1324-30.
- 6 Yamamoto S, Mizoue T, Tanaka A, et al. Sex-associated differences between BMI and SARS-CoV-2 antibody titers following the BNT162b2 vaccine. *Obesity (Silver Spring)* 2022; **30**: 999-1003.
- 7 Piernas C, Patone M, Astbury NM, et al. Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study. *Lancet Diabetes Endocrinol* 2022; published online June 30. [https://doi.org/10.1016/S2213-8587\(22\)00158-9](https://doi.org/10.1016/S2213-8587(22)00158-9).
- 8 Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. *N Engl J Med* 2020; **383**: 2603-15.
- 9 Patel MK, Bergeri I, Bresee JS, et al. Evaluation of post-introduction COVID-19 vaccine effectiveness: summary of interim guidance of the World Health Organization. *Vaccine* 2021; **39**: 4013-24.
- 10 Robinson E, Boyland E, Chisholm A, et al. Obesity, eating behavior and physical activity during COVID-19 lockdown: a study of UK adults. *Appetite* 2021; **156**: 104853.



## Second brain tumours after pituitary irradiation: lower risk than once thought

Published Online  
June 30, 2022  
[https://doi.org/10.1016/S2213-8587\(22\)00171-1](https://doi.org/10.1016/S2213-8587(22)00171-1)

Since its first proposal in the treatment of pituitary tumours more than a century ago, indications for cranial radiotherapy have notably evolved. In rare

pituitary carcinomas, indication of radiotherapy remains undisputable after surgical treatment in case of remnant tumour or recurrence. Until the availability of effective